Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026)
Minerva Neurosciences (NERV) posted Amortizatization of Intangibles of $136741.0 for Q1 2026, up 3112.14% on a QoQ basis from $4257.0 in Q3 2024.
Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Minerva Neurosciences' Amortizatization of Intangibles history runs 12 years deep, the most recent figure standing at $136741.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $136741.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136741.0 (up 1184.92% YoY) and the FY2024 annual result came in at $17027.0, down 33.33% from the prior year.
- Amortizatization of Intangibles was $136741.0 for Q1 2026 at Minerva Neurosciences, up from $4257.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $136741.0 in Q1 2026 and bottomed at $4257.0 in Q3 2024.
- A 4-year average of $20632.6 and a median of $6385.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles changed 0.0% — and 2024, when it tumbled 33.33%.
- Minerva Neurosciences' Amortizatization of Intangibles stood at $6385.0 in 2022, then changed by 0.0% to $6385.0 in 2023, then tumbled by 33.33% to $4257.0 in 2024, then jumped by 3112.14% to $136741.0 in 2026.
- Business Quant data shows NERV's Amortizatization of Intangibles at $136741.0 in Q1 2026, $4257.0 in Q3 2024, and $6385.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Minerva Neurosciences | 185.26 Mn | 185.26 Mn | - | 136,741.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136,741.00 |
| Mar 31, 2026 | 136,741.00 |
| Sep 30, 2024 | 4,257.00 |
| Sep 30, 2024 | 4,257.00 |
| Jun 30, 2024 | 6,385.00 |
| Jun 30, 2024 | 6,385.00 |
| Mar 31, 2024 | 6,385.00 |
| Mar 31, 2024 | 6,385.00 |
| Dec 31, 2023 | 6,385.00 |
| Dec 31, 2023 | 6,385.00 |
| Sep 30, 2023 | 6,385.00 |
| Sep 30, 2023 | 6,385.00 |
| Jun 30, 2023 | 6,385.00 |
| Jun 30, 2023 | 6,385.00 |
| Mar 31, 2023 | 6,385.00 |
| Mar 31, 2023 | 6,385.00 |
| Dec 31, 2022 | 6,385.00 |
| Dec 31, 2022 | 6,385.00 |
| Sep 30, 2021 | 14,939.00 |
| Sep 30, 2021 | 14,939.00 |